Curated News
By: NewsRamp Editorial Staff
June 20, 2025
Annovis Bio Granted NYSE Compliance Extension for Neurodegenerative Therapies
TLDR
- Annovis Bio gains an 18-month extension from NYSE to meet listing requirements, offering investors a window to capitalize on its neurodegenerative disease therapies development.
- Annovis Bio's compliance plan accepted by NYSE outlines specific milestones to regain listing standards, ensuring continued trading without operational disruptions.
- Annovis Bio's work on therapies for Alzheimer’s and Parkinson’s promises to enhance patient quality of life by targeting multiple neurotoxic proteins.
- Exploring Annovis Bio's innovative approach to neurodegeneration reveals a potential breakthrough in treating Alzheimer’s and Parkinson’s diseases.
Impact - Why it Matters
This news is significant for investors and patients alike, as Annovis Bio's work in developing treatments for Alzheimer’s and Parkinson’s diseases represents a beacon of hope for millions affected by these conditions. The NYSE's compliance extension ensures the company can continue its critical research without operational disruptions, potentially accelerating the availability of groundbreaking therapies.
Summary
Annovis Bio (NYSE: ANVS), a clinical-stage platform company focused on developing therapies for neurodegenerative diseases such as Alzheimer’s and Parkinson’s, has been granted an 18-month extension by the New York Stock Exchange to meet compliance standards regarding minimum market capitalization and stockholders’ equity. This decision allows Annovis Bio to continue trading on the NYSE, ensuring its operations and business activities remain unaffected. The company, based in Malvern, Pennsylvania, is dedicated to innovating treatments that target multiple neurotoxic proteins, aiming to enhance brain function and patient quality of life. For more details, visit the full press release.
Annovis Bio's commitment to addressing neurodegeneration is supported by its presence on various platforms, including its website, LinkedIn, X, and YouTube. The company's progress and updates are also available in its newsroom at https://ibn.fm/ANVS.
Source Statement
This curated news summary relied on content disributed by InvestorBrandNetwork (IBN). Read the original source here, Annovis Bio Granted NYSE Compliance Extension for Neurodegenerative Therapies
